Faslodex is an oestrogen receptor antagonist, which can bind, block and degrade the oestrogen receptor, thereby helping in the treatment of hormone receptor-positive metastatic breast cancer which has recurred after an endocrine therapy in postmenopausal women.
Faslodex also disrupts oestrogen signalling, causing down-regulation of the oestrogen receptors in the tumour, which prevents the spread of the cancer.
The results of the Phase III Confirm study led to the approval of Faslodex 500mg in Europe in March 2010 and the US in September 2010.
AstraZeneca Global Commercial Organisation executive vice president Tony Zook said metastatic breast cancer treatment primarily aims to prevent disease progression besides maintaining quality of life and Faslodex 500mg will provide better control over the disease.